Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 6/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2476439 | 0.88 | CXCR4 (0.44) | OPRL1CXCR4DRD2DRD3 | |
| SCHEMBL26523222 | 0.87 | CXCR4 (0.43) | OPRL1CXCR4DRD2DRD3 | |
| SCHEMBL26107971 | 0.87 | CXCR4 (0.43) | OPRL1CXCR4DRD2DRD3 | |
| SCHEMBL30586952 | 0.87 | CXCR4 (0.43) | OPRL1CXCR4DRD2DRD3 | |
| SCHEMBL30586948 | 0.86 | OPRL1 (0.41) | OPRL1CXCR4DRD2ADRA1ADRD3 | |
| SCHEMBL26110868 | 0.86 | OPRL1 (0.41) | OPRL1CXCR4DRD2ADRA1ADRD3 | |
| SCHEMBL4244954 | 0.84 | ATM (0.37) | OPRL1CXCR4ATM | |
| SCHEMBL2475603 | 0.84 | SCN8A (0.49) | ALDH1A1OPRL1CXCR4DRD2ADRA1A | |
| SCHEMBL2476696 | 0.83 | CXCR4 (0.42) | OPRL1CXCR4ATM | |
| SCHEMBL2473403 | 0.83 | ATM (0.41) | ALDH1A1KDM4EOPRL1CXCR4ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281308-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED, INC. (CA) | 2009-11-12 | — | — | US | disclosed |
| US-20090281308-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED, INC. (CA) | 2009-11-12 | — | — | US | disclosed |
| US-7550484-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550484-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| WO-2004093817-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281308-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CXCR4, CXCR1, CCR5 | ALDH1A1 290/4885KDM4E 3731/4885OPRL1 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.